1、Evaluating Equity in Accessing Long-Acting Injectable Antiretroviral Therapy at a Ryan White Clinic in New Orleans,LouisianaTat Yau,MD,MPHLSU Health New OrleansCo-authors:Brandon Nguyen PharmD,Wade Wheat PharmD,Brenda Simiyu PharmD,Paula Seal MD MPH,Meredith Clement MD,Lauren Richey MD MPHSeptember
2、15-17,2025IntroductionLong-acting injectable(LAI)antiretroviral therapy(ART)cabotegravir-rilpivirine(CAB-RPV)was approved by the U.S.Food and Drug Administration(FDA)in January 2021 1.The less frequent dosing of LAI ART aims to eliminate pill fatigue and the associated stigma 2.1.ViiV Healthcare.Cab
3、enuva prescribing information.2022.2.Nachega et.al.2023.The lancet.HIV,10(5),e332e342.September 15-17,2025IntroductionWe describe the equity of LAI CAB-RPV use at the HIV Outpatient Program(HOP)at University Medical Center New Orleans(UMCNO).September 15-17,2025DescriptionPeople with HIV(PWH)at our
4、clinic transitioned from traditional oral ART to LAI CAB-RPV were evaluated and analyzed:AgeSex assigned at birthGender identityEthnicityHousing statusEmploymentInsurance coverageCD4 countsHIV viral loadSeptember 15-17,2025Lessons Learned32 PWH transitioned to CAB-RPV as of September 2024:Median age
5、 was 42(33-53).60%were male(compared to 67%clinic population)2(6%)were transgender(compared to 1.7%clinic population)81%were black(compared to 75%clinic population)81%had stable housing(compared to 95%clinic population)69%were employed 78%had Medicaid insurance(compared to 45%clinic population)Septe
6、mber 15-17,2025Lessons LearnedThe median CD4 count/percentage prior to initiation of CAB-RPV was 543(32.4%).Most patients except for one had a viral load less than 200 copies/mL prior to initiation of CAB-RPV.September 15-17,2025RecommendationsAs compared to o